{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:19:34Z","timestamp":1785410374318,"version":"3.56.0"},"reference-count":44,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Gastrointestinal stromal tumors (GIST) are rare sarcomas arising predominantly in the stomach and small intestine, with limited incidence in other gastrointestinal sites. GIST originates from c-KIT\u2013\/DOG1-positive interstitial cells of Cajal (ICC) most commonly driven by activating gain-of-function mutations in the c-KIT and PDGFRA genes. However, a subset of these malignancies, defined as wild-type GIST (WT-GIST), has mutations in the RAS pathway genes (e.g., NF1, KRAS, and BRAF), succinate dehydrogenase subunit genes, and rare gene fusions. A major obstacle in understanding WT-GIST pathogenesis and treatment resistance has been the lack of robust in vivo models. In this study, we report the development of a fully penetrant mouse model of BRAF-driven GIST by inducing BRAFV600E expression in c-Kit+ ICC. Unlike previous models which targeted only subsets of ICC leading to hyperplasia, the use of c-KitCreERT2 enables broader targeting, including ICC progenitors, resulting in rapid, multifocal tumor formation primarily in the pyloric region. These tumors express diagnostic GIST markers (c-Kit and DOG1) and show significant response to the BRAF inhibitor dabrafenib. This model recapitulates key histopathologic and molecular features of human BRAF-mutant GIST and provides a valuable platform for studying tumor initiation, progression, and therapeutic resistance. Importantly, it allows for preclinical testing of targeted therapies in BRAF GIST, offering new insights into treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This is the first fully penetrant mouse model of BRAF-driven GIST by inducing BRAFV600E in c-Kit+ ICC. This model faithfully recapitulates human BRAF-mutant GIST, enabling mechanistic studies and preclinical testing of targeted therapies, including response to BRAF inhibition with dabrafenib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0725","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:45:31Z","timestamp":1771260331000},"page":"557-565","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<i>BRAF<\/i>\n                    V600E Expression in c-Kit+ Interstitial Cells of Cajal Drives Gastrointestinal Stromal Tumor Formation in Mice"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8824-3693","authenticated-orcid":false,"given":"Francesco","family":"Tomassoni-Ardori","sequence":"first","affiliation":[{"name":"NCI 1 Mouse Cancer Genetics Program (MCGP), Center for Cancer Research, , NIH, Frederick, Maryland."},{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"NCI 2 My Pediatric and Young Adult Rare Tumor (MyPART) Network, , NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9109-4409","authenticated-orcid":false,"given":"Karlyne M.","family":"Reilly","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"NCI 2 My Pediatric and Young Adult Rare Tumor (MyPART) Network, , NIH, Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 3 Pediatric Oncology Branch, Center for Cancer Research, , National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2723-3186","authenticated-orcid":false,"given":"Colleen","family":"Barrick","sequence":"additional","affiliation":[{"name":"NCI 1 Mouse Cancer Genetics Program (MCGP), Center for Cancer Research, , NIH, Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7633-0780","authenticated-orcid":false,"given":"Robert","family":"Koogle","sequence":"additional","affiliation":[{"name":"NCI 1 Mouse Cancer Genetics Program (MCGP), Center for Cancer Research, , NIH, Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6106-3705","authenticated-orcid":false,"given":"Elijah F.","family":"Edmondson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v6m3209","id-type":"ROR","asserted-by":"publisher"}],"name":"Frederick National Laboratory for Cancer Research 4 Molecular Histopathology Laboratory, Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc., , Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5929-4822","authenticated-orcid":false,"given":"Sudhirkumar","family":"Yanpallewar","sequence":"additional","affiliation":[{"name":"NCI 1 Mouse Cancer Genetics Program (MCGP), Center for Cancer Research, , NIH, Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5874-0210","authenticated-orcid":false,"given":"Dieter","family":"Saur","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02kkvpp62","id-type":"ROR","asserted-by":"publisher"}],"name":"Technical University of Munich 5 Department of Medicine 2, Klinikum rechts der Isar, , Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-7175","authenticated-orcid":false,"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"NCI 2 My Pediatric and Young Adult Rare Tumor (MyPART) Network, , NIH, Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 3 Pediatric Oncology Branch, Center for Cancer Research, , National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3071-7876","authenticated-orcid":false,"given":"John W.","family":"Glod","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"NCI 2 My Pediatric and Young Adult Rare Tumor (MyPART) Network, , NIH, Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 3 Pediatric Oncology Branch, Center for Cancer Research, , National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6420-772X","authenticated-orcid":false,"given":"Lino","family":"Tessarollo","sequence":"additional","affiliation":[{"name":"NCI 1 Mouse Cancer Genetics Program (MCGP), Center for Cancer Research, , NIH, Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2026031301385344200_bib1","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/ncomms2626","article-title":"Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow-wave activity","volume":"4","author":"Klein","year":"2013","journal-title":"Nat Commun"},{"key":"2026031301385344200_bib2","first-page":"769","article-title":"Identification of the interstitial cells of Cajal","volume":"11","author":"Komuro","year":"1996","journal-title":"Histol Histopathol"},{"key":"2026031301385344200_bib3","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1582-4934.2006.tb00541.x","article-title":"Interstitial cells of Cajal (ICC) and gastrointestinal stromal tumor (GIST): facts, speculations, and myths","volume":"10","author":"Min","year":"2006","journal-title":"J Cell Mol Med"},{"key":"2026031301385344200_bib4","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0002-9440(10)64984-X","article-title":"Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal","volume":"156","author":"Robinson","year":"2000","journal-title":"Am J Pathol"},{"key":"2026031301385344200_bib5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/cancers11050679","article-title":"Clinical diagnosis of gastrointestinal stromal tumor (GIST): from the molecular genetic point of view","volume":"11","author":"Wu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026031301385344200_bib6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/PAP.0000000000000463","article-title":"Gastrointestinal stromal tumors: variants and some pitfalls that they create","volume":"31","author":"Ibrahim","year":"2024","journal-title":"Adv Anat Pathol"},{"key":"2026031301385344200_bib7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/107327481502200416","article-title":"Is DOG1 immunoreactivity specific to gastrointestinal stromal tumor?","volume":"22","author":"Swalchick","year":"2015","journal-title":"Cancer Control"},{"key":"2026031301385344200_bib8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"key":"2026031301385344200_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"2026031301385344200_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","article-title":"Gastrointestinal stromal tumors: pathology and prognosis at different sites","volume":"23","author":"Miettinen","year":"2006","journal-title":"Semin Diagn Pathol"},{"key":"2026031301385344200_bib11","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41591-023-02734-5","article-title":"Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial","volume":"30","author":"Heinrich","year":"2024","journal-title":"Nat Med"},{"key":"2026031301385344200_bib12","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.2165\/11635590-000000000-00000","article-title":"Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management","volume":"72","author":"Joensuu","year":"2012","journal-title":"Drugs"},{"key":"2026031301385344200_bib13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0140-6736(13)60106-3","article-title":"Gastrointestinal stromal tumour","volume":"382","author":"Joensuu","year":"2013","journal-title":"Lancet"},{"key":"2026031301385344200_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40265-022-01820-1","article-title":"TKI treatment sequencing in advanced gastrointestinal stromal tumors","volume":"83","author":"Khosroyani","year":"2023","journal-title":"Drugs"},{"key":"2026031301385344200_bib15","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","article-title":"Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health gastrointestinal stromal tumor clinic","volume":"2","author":"Boikos","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026031301385344200_bib16","doi-asserted-by":"crossref","first-page":"e2400497","DOI":"10.1200\/PO-24-00497","article-title":"Targeted next-generation sequencing in succinate dehydrogenase-deficient GI stromal tumor Identifies actionable alterations in the PI3K\/mTOR pathway","volume":"9","author":"Cicala","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"2026031301385344200_bib17","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3390\/cancers16091707","article-title":"Utility of clinical next generation sequencing tests in KIT\/PDGFRA\/SDH wild-type gastrointestinal stromal tumors","volume":"16","author":"Denu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026031301385344200_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/pin.12431","article-title":"\u201cWild type\u201d GIST: clinicopathological features and clinical practice","volume":"66","author":"Wada","year":"2016","journal-title":"Pathol Int"},{"key":"2026031301385344200_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00014","article-title":"Duodenal-jejunal flexure GI stromal tumor frequently heralds somatic NF1 and Notch pathway mutations","volume":"1","author":"Burgoyne","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2026031301385344200_bib20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.18632\/oncotarget.864","article-title":"BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance","volume":"4","author":"Falchook","year":"2013","journal-title":"Oncotarget"},{"key":"2026031301385344200_bib21","doi-asserted-by":"crossref","first-page":"788","DOI":"10.21037\/jgo-23-767","article-title":"Treatment of BRAF V600E mutant gastrointestinal stromal tumor with dabrafenib: a case report","volume":"15","author":"Gowda","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"2026031301385344200_bib22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/gcc.22230","article-title":"Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing","volume":"54","author":"Hechtman","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"2026031301385344200_bib23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.humpath.2017.01.005","article-title":"Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT\/PDGFRA wild-type GISTs are rare events","volume":"62","author":"Huss","year":"2017","journal-title":"Hum Pathol"},{"key":"2026031301385344200_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/01.pas.0000176433.81079.bd","article-title":"Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases","volume":"30","author":"Miettinen","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"2026031301385344200_bib25","first-page":"4248128","article-title":"Gastrointestinal stromal tumours (GISTs) with KRAS mutation: a rare but important subset of GISTs","volume":"2023","author":"Mullen","year":"2023","journal-title":"Case Rep Gastrointest Med"},{"key":"2026031301385344200_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","article-title":"Gastrointestinal stromal tumours","volume":"7","author":"Blay","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026031301385344200_bib27","doi-asserted-by":"crossref","first-page":"1588950","DOI":"10.3389\/fonc.2025.1588950","article-title":"Case Report: dramatic response to entritinib in a patient with gastrointestinal stromal tumor positive for NTRK3 fusion","volume":"15","author":"Dong","year":"2025","journal-title":"Front Oncol"},{"key":"2026031301385344200_bib28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12967-016-1075-6","article-title":"FGFR1 and NTRK3 actionable alterations in \u201cWild-Type\u201d gastrointestinal stromal tumors","volume":"14","author":"Shi","year":"2016","journal-title":"J Transl Med"},{"key":"2026031301385344200_bib29","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1158\/0008-5472.CAN-16-3510","article-title":"ETV1-positive cells give rise to BRAFV600E -mutant gastrointestinal stromal tumors","volume":"77","author":"Ran","year":"2017","journal-title":"Cancer Res"},{"key":"2026031301385344200_bib30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/path.5552","article-title":"A smooth muscle-derived, Braf-driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell-of-origin","volume":"252","author":"Kondo","year":"2020","journal-title":"J Pathol"},{"key":"2026031301385344200_bib31","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1053\/j.gastro.2008.02.074","article-title":"Progenitor cells of interstitial cells of Cajal: on the road to tissue repair","volume":"134","author":"Huizinga","year":"2008","journal-title":"Gastroenterology"},{"key":"2026031301385344200_bib32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/373347a0","article-title":"W\/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity","volume":"373","author":"Huizinga","year":"1995","journal-title":"Nature"},{"key":"2026031301385344200_bib33","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.3390\/ijms25094633","article-title":"RAF and MEK inhibitors in non-small cell lung cancer","volume":"25","author":"Adamopoulos","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026031301385344200_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2026031301385344200_bib35","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"2026031301385344200_bib36","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1073\/pnas.1037763100","article-title":"Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase","volume":"100","author":"Sommer","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026031301385344200_bib37","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1038\/s41388-020-01489-4","article-title":"The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"key":"2026031301385344200_bib38","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1152\/physiolgenomics.00113.2007","article-title":"Differential gene expression in functional classes of interstitial cells of Cajal in murine small intestine","volume":"31","author":"Chen","year":"2007","journal-title":"Physiol Genomics"},{"key":"2026031301385344200_bib39","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nature09409","article-title":"ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours","volume":"467","author":"Chi","year":"2010","journal-title":"Nature"},{"key":"2026031301385344200_bib40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.gastro.2015.04.018","article-title":"LRIG1 regulates ontogeny of smooth muscle-derived subsets of interstitial cells of Cajal in mice","volume":"149","author":"Kondo","year":"2015","journal-title":"Gastroenterology"},{"key":"2026031301385344200_bib41","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1053\/j.gastro.2008.01.036","article-title":"Progenitors of interstitial cells of Cajal in the postnatal murine stomach","volume":"134","author":"Lorincz","year":"2008","journal-title":"Gastroenterology"},{"key":"2026031301385344200_bib42","first-page":"1","article-title":"Old and new immunohistochemical markers for the diagnosis of gastrointestinal stromal tumors","volume":"33","author":"Gonz\u00e1lez-C\u00e1mpora","year":"2011","journal-title":"Anal Quant Cytol Histol"},{"key":"2026031301385344200_bib43","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/modpathol.3880210","article-title":"Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT)","volume":"13","author":"Miettinen","year":"2000","journal-title":"Mod Pathol"},{"key":"2026031301385344200_bib44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.gastro.2021.10.028","article-title":"Gastroparesis","volume":"162","author":"Camilleri","year":"2022","journal-title":"Gastroenterology"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0725\/3738085\/crc-25-0725.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/557\/3747276\/crc-25-0725.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/557\/3747276\/crc-25-0725.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:39:12Z","timestamp":1773380352000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/3\/557\/775245\/BRAFV600E-Expression-in-c-Kit-Interstitial-Cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0725","relation":{},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}